Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Capital Strength ESG Leaders UCITS ETF 17.02.2026 FCSG IE00BKPSPT20 1,400,002.00 USD 62,230,534.60 44.450  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 17.02.2026 UNCU.LN IE00BD6GCF16 816,921.00 USD 37,076,722.18 45.386  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 17.02.2026 FXGB LN IE00BD5HBR05 37,992.00 GBP 756,458.36 26.887  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Equity Income UCITS ETF 17.02.2026 UINC IE00BZBW4Z27 9,869,448.00 USD 376,182,413.78 38.116  ...

WALTHAM, Mass.--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for devastating cardiovascular diseases, today announced that the European Medicines Agency (EMA) has granted Orphan Drug designation to Affinia for AFTX-201. AFTX-201 is a potential first-in-class and best-in-class investigational genetic medicine for the treatment of BAG3-associated di...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 17.02.2026 FTFX IE00BD5HBQ97 63,402.00 USD 1,671,297.59 26.360  ...

CAESAREA, Israel--(BUSINESS WIRE)--Delta Galil Industries, Ltd. today reported financial results for the fourth quarter and year ended December 31, 2025....

MILWAUKEE--(BUSINESS WIRE)--Zywave launches four insurance-specialized AI agents to streamline workflows and help brokers drive faster, smarter growth....

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its fourth quarter and full year 2025 financial results and business updates on Wednesday, March 4, 2026, at 4:30 pm ET. To access the conference call, please dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) and enter the passco...

HOUSTON--(BUSINESS WIRE)--Starlab Space LLC, the commercial space station developer expanding access to low Earth orbit research, today announced a partnership with Helogen Corporation, the automation platform industrializing orbit by enabling scalable, regulatory-grade manufacturing and autonomous biological operations in space. Together, the companies will expand how life sciences research is conducted in microgravity, moving from isolated experiments toward persistent, scalable discovery in...